Category: IRX4204

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

July 9, 2024

•

Investor Empires

This section is Partnership Content Provided The content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe Newswire Breadcrumbs Path Links Globe Newswire Article author: Published on July 9, 2024 •…